Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06334575 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06334575 · ClinicalTrials.gov record · last posted 2026-07-20

Molecular Signatures Associated With Response to ICS Treatment in Patients With COPD Stratified by Eosinophil Levels

Study acronym: 3TR-ICS-COPD
StatusRecruiting
PhasePhase 4
Started2025-02-12
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The 3TR-ICS COPD study is an international, multicentre, randomized, parallel, controlled study that will recruit clinically stable former smokers COPD patients (with no exacerbations in the previous 8 weeks) on treatment with dual long-acting bronchodilators (LABA+LAMA), minimum 8 weeks of usage, not receiving ICS (either naïve or \> 3 months since last usage). The overall objective of this clinical trial is to identify the molecular signatures associated with the molecular response to ICS treatment in patients with COPD stratified by the levels of circulating eosinophils, and the potential influence of the pulmonary microbiome

Amendment record 3 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 3 times since 2024-03-21; most recent amendment 2026-07-17. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2025-03-10
Status change Not Yet Recruiting→Recruitingv1
Trial Details
NCT Number NCT06334575
Lead Sponsor Maria Joyera Rodríguez
Conditions Chronic Obstructive Pulmonary Disease
Enrollment 135 participants
Start Date 2025-02-12
Primary Completion 2027-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-20